RJ Hamster
RJ Hamster
RJ Hamster
RJ Hamster
Self-Dignity Is the Foundation of Health—Here’s How to Build…
for Subscribers Only
February 12, 2026
Self-Dignity Is the Foundation of Health—Here’s How to Build It
from Chrisy Trudeau
Managing Editor
Good Morning!
Most of us already know what we shouldbe doing for our health: sleep more, move regularly, eat real food, spend less time on our phones. The hard part isn’t knowing what to do, it’s the sting of falling short. That quiet disappointment when we stay up scrolling instead of resting, or reach for comfort food we don’t even really want, cuts deeper than we like to admit. It’s about feeling out of sync with the kind of person we believe we are.
That gap between what we value and how we act is where dignity lives. Health isn’t simply the absence of disease or the presence of good habits. It’s also the ongoing answer to a deeper question: Do I treat myself like someone who matters?
Each choice to cook instead of grab takeout or to go for a walk instead of collapsing into the couch strengthens or weakens that sense of self-respect. Over time, living out of alignment doesn’t just show up in our bodies; it shows up as exhaustion, numbness, and the nagging feeling that we’re letting ourselves down in small ways every day.
Chiropractor and functional medicine expert James Chestnut said, “Integrity is everything—it’s the most lucrative asset you could ever have.” He’s not talking about being perfect. He’s talking about the simple but powerful act of matching what we say we value with what we actually do. Seen that way, health practices become less about willpower and more about dignity in motion. Eating well, moving often, resting deeply, and setting boundaries stop being boxes to tick and start becoming concrete ways of saying, “I matter. My body, my time, and my future are worthy of respect.”
From this perspective, self-dignity isn’t some abstract ideal. It’s the invisible foundation that makes real, lasting health possible.
Read this week’s feature by Epoch Times health expert Sheridan Genrich, a clinical nutritionist and naturopath, as she unpacks what dignity really means for our health and how we can start weaving more of it into everyday life.
Wishing you are health body and a strong mind,
READ FULL ARTICLE HERE
Self-Dignity Is the Foundation of Health—Here’s How to Build It
MORE ON SELF-CARE
When Trying Hard Isn’t Enough: How to Break Through Feeling Stuck
When “trying harder” backfires, the problem usually isn’t laziness—it’s a nervous system that’s overloaded, perfectionistic goals that are too big or brittle, and a harsh inner critic that turns every slip into “failure.”
Clutter—both in our homes and in our heads—quietly drains focus, fuels stress, and disrupts daily life. Clearing physical and mental clutter can lift mood, sharpen thinking, and restore a steadier sense of calm control.
THIS WEEK’S MUST WATCH
Your Body Doesn’t Need Sugar. Here’s What Happens When You Quit
Cutting added sugar—even briefly—can rapidly transform energy, cravings, metabolism, and mood in ways that go far beyond simple weight loss.
Thanks for reading. Stay tuned for our next edition coming your way next week.
Want to wake up with us every morning?
Subscribe to Rise & Shine.
Thank you for being a subscriber!
If you love this newsletter, please share it with your friends and let them know they can sign up and browse all of our newsletters here.
Your Feedback
We’d love to hear from you. If you have any suggestions for us to improve or a wellness story that you’d like us to cover, you can email me at healthnewsletter@epochtimes.nyc
We may feature an excerpt of your response in the next newsletter.
You are receiving this email because you subscribed to The Epoch Times.
The information in this newsletter is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of many experts and journalists. The Epoch Times encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional.
Copyright © 2025 The Epoch Times.
All rights reserved.
229 W 28th St, Fl.5, New York, NY 10001
Terms & Conditions | Customer Service | Privacy Policy| Manage Email Preferences Unsubscribe
RJ Hamster
The difference between holding and trading a 30-minute window
Gold investors have watched 20% evaporate in a single day.
Bitcoin holders have lost up to 47% since October.
If you’re a buy-and-hold investor right now, you’re getting whiplashed.
You buy the dip. It dips more.
You hold through the volatility. It gets more volatile.
You wake up to news that should be good… and your stock is down 17% anyway.
And here’s the worst part:
You can’t do anything about it.
You’re married to the position. You’re either holding and hoping, or you’re selling at a loss and watching it rip the next day.
Every morning you wake up wondering what happened overnight.
Every headline makes your stomach turn.
Every swing feels personal.
Because you’re HOLDING. You’re exposed. You’re waiting for the market to do what you need it to do.
That’s not trading. That’s hoping.
Now contrast that with what Brian showed you in yesterday’s workshop:
You trade a 30-minute wave at the 9:30 open.
You get in. You take profit. You close the position. 9:45am, you’re done.
What happens to gold after that? Doesn’t matter. You’re out.
What happens to tech stocks at 2pm? Doesn’t matter. Your position is closed.
What happens overnight while you sleep? Doesn’t matter. You have zero exposure.
You don’t care if AMD beats earnings and dumps 17%.
You don’t care if Bitcoin crashes another 20%.
You don’t care if the market rips or tanks after you walk away.
Because you already locked your profit.
Position closed. Day done.
That’s the difference between investing and day trading wave windows.
Investors are exposed to everything – overnight gaps, earnings surprises, headline risk, geopolitical chaos, random CEO tweets.
Day traders who trade specific windows? Exposed to 30 minutes of price action. That’s it.
And in 2026, when everything is moving and nothing makes sense…
When buy-and-hold is getting stress-tested daily…
When gold can swing 20% in a day and Bitcoin can lose half its value in three months…
Trading short wave windows and walking away is the sanest approach I’ve seen.
If you want to see exactly how this works – the specific wave windows Brian trades, the entry rules, how to qualify for funded accounts – the replay is still available:
>> Click here to watch the webinar replay now
It expires tomorrow at 6pm EST, so don’t procrastinate.
Mark Soberman
NetPicks
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT ADVICE. NetPicks Services are offered for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation or be relied upon as personalized financial advice. We are not financial advisors and cannot give personalized advice. There is a risk of loss in all trading, and you may lose some or all of your original investment. Results presented are not typical. Please review the full risk disclaimer: https://www.netpicks.com/risk-disclosure This email was sent to pahovis@aol.com by info@netpicks.com
16211 N Scottsdale Rd, Suite A6A #295, Scottsdale, AZ 85254
RJ Hamster
ISPC: From Small Cap to Life Sciences Market Disruptor!
This Under-the-Radar Life Sciences Platform is Transforming Biospecimen Access in a $4 Billion Market!
iSpecimen Inc. (NASDAQ: ISPC) is quietly revolutionizing the way medical research sources human biospecimens through its cloud-based iSpecimen Marketplace®.
By connecting researchers directly with hospitals, labs, and biobanks worldwide, the platform dramatically accelerates access to high-quality specimens while ensuring compliance and documentation—solving a bottleneck that has long slowed innovation in precision medicine, regenerative therapies, and diagnostics.
With over 7,500 registered users and more than 105 supplier organizations, ISPC is showing real operational traction in a market poised for modernization.
The company’s platform-driven model provides tangible revenue opportunities for providers and a faster, more reliable procurement process for researchers.
Supported by a financial strategy that maintains flexibility for growth and partnerships, ISPC is building scalable infrastructure for the future of biomedical research.
This is a rare opportunity: a small-cap company with real operational traction, a first-mover advantage in a $3–4 billion market, and a platform poised to redefine biospecimen access.
Discover why ISPC is a small-cap life sciences stock investors should be watching
This message is a paid advertisement for iSpecimen Inc. (NASDAQ: ISPC) from Stocks.News and Organized Noise. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $50,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Stocks.News or Organized Noise. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding iSpecimen Inc. (NASDAQ: ISPC) on Organized Noise’ website for additional information about the relationship between Organized Noise and iSpecimen Inc. (NASDAQ: ISPC) .
Update your email preferences or unsubscribe here
© 2026 American Market News
345 N Reid Place #620
Sioux Falls, SD 57103, United StatesTerms of Service
RJ Hamster
A New Player’s Rising to Secure the West’s Metal…
This is a paid advertisement. Full disclosures and risk factors are provided at the bottom of this email.
Dear Reader,
Building the Metals Backbone for the Free World
Critical metals are the backbone of national strength – but most still come from abroad.
One North American company is working to change that, developing resources that could strengthen the West’s energy grid, defense manufacturing, and supply security.
See how this emerging firm is helping fortify the West’s supply chain
DISCLOSURES – THIS IS A PAID ADVERTISEMENT.
This is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public and private companies. By reading this email, our website / media webpage you agree to the terms of our disclosure, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing.
This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.
In connection with this advertising e-mail campaign, The Darwin Agency, Inc, DBA Darwin Investor Network, and its owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case, the Company has been paid by i2i Marketing Group, Two Thousand ($2,000.00) USD, which itself is being compensated by a third party,Saga Metals Corp., a publicly traded company, for advertising services including brand awareness, marketing distribution and investor education marketing for a period beginning February 3rd and to conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict with our ability to be unbiased.
NOT AN INVESTMENT ADVISER. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.
ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our featured profiles on the highlighted companies. Gains mentioned in our website / media webpage(s) may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.
For official filings and investor disclosures, visit:
By accessing this information, you acknowledge and agree that Darwin Investor Network, its affiliates, owners, and representatives are not liable for any financial or investment decisions based on this communication.Advertising Disclosure: This email contains paid advertisements. This email is from our associates at i2i .
Legal Entity Information: Investing Ideas Daily is owned and operated by Darwin Investor Network, a DBA of The Darwin Agency, Inc.
Disclaimer: Nothing in this email should be considered personalized financial advice. Always conduct your own due diligence when investing. We urge you to read our full disclaimer by clicking on the terms of use link below.
Unsubscribe: You are receiving this email as part of your complimentary subscription to the Investing Ideas Daily E-Letter. If you would like to unsubscribe, you can do so by clicking on the unsubscribe link below.Darwin Investor Network
2319 N Andrews Avenue, Fort Lauderdale, FL 33311
support@investingideasdaily.com | 1-800-496-9838Investing Ideas Daily | Privacy Policy | Terms of Use
Unsubscribe | View Online
RJ Hamster
🌎 Coinbase Global Downgraded, Hexcel Upgraded, Huntington Ingalls Industries…
Ratings changes for LightPath Technologies, Coinbase Global, Shopify, Sezzle, GlobalFoundries, Cisco Systems, AppLovin and more…Upgrade to MarketBeat All Access to get our best stock ideas, proprietary research, portfolio monitoring tools, and more. Start Your Free Trial.
FEBRUARY 12TH, 2026
Trump’s Final Shocking Act Begins February 24 (ad)After signing more than 220 Executive Orders… more than any president in American history… Donald Trump is preparing for one final move.
On February 24th — I have every reason to believe he will sign his Final Executive Order.
When I say that it’s his FINAL executive order…
CLICK HERE OR BELOW FOR THIS UNBELIEVABLE STORY…
Today’s Top Stories
Offshore Titans: Transocean Buys Valaris for $5.8B
BY JEFFREY NEAL JOHNSON | FEBRUARY 12, 2026 07:30 AM
Starlink pre-IPO opportunity with this $30 stock (Ad)
BY PARADIGM PRESS
BlueBird 6 Unfolds: AST SpaceMobile Unlocks Commercial Growth
BY JEFFREY NEAL JOHNSON | FEBRUARY 12, 2026 06:17 AM
Cloudflare: Another AI-Disrupted Stock You Might Want to Buy
BY THOMAS HUGHES | FEBRUARY 11, 2026 05:41 PM
FOR SALE: Massive Public Land Auction (Ad)
BY STANSBERRY RESEARCH
GE Vernova Rallies on the AI Grid Supercycle: Turbines, Transformers, and Cash Returns
BY JEFFREY NEAL JOHNSON | FEBRUARY 11, 2026 12:25 PM
Ahead of Q4 Earnings, CoreWeave Is Up 142% Over the Past Year
BY JORDAN CHUSSLER | FEBRUARY 10, 2026 10:19 AM
Quick Links
Analyst RatingsMy MarketBeatAccount SettingsMarketBeat All AccessStock ListsStock ScreenerCalculatorsPremium ReportsBest Stocks to Buy in FebruaryElon Musk’s Frightening Warning Forces Trump’s Hand (ad)For the everyday American who’s worked hard to build their nest egg, Trump preserved a IRS loophole that allows you to protect your retirement savings before billions in American wealth are lost.
Download Your Free 2026 Wealth Protection Guide and execute the simple steps to protect your future.
GET THE FREE GUIDE
Your Watchlist
MANAGE YOUR WATCHLIST AND MONITOR YOUR PORTFOLIO
$272.97 -2.53 (-0.92%) As of 2/12/2026 9:40 AM ET
- Apple Inc. (NASDAQ:AAPL) declared a quarterly dividend on Thursday, January 29th. Investors of record on Monday, February 9th will be paid a dividend of 0.26 per share by the iPhone maker on Thursday, February 12th. This represents a c) annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, February 9th.
- Mag 7 AI Arms Race: Heavy Capex, FCF Strain and One Clear Winner 2/12 – ZACKS
- Ycg LLC Acquires 22,444 Shares of Apple Inc. $AAPL 2/12 – MARKETBEAT
- Vectors Research Management LLC Has $8.23 Million Stake in Apple Inc. $AAPL2/12 – MARKETBEAT
- Palo Alto, Apple, Visa And A Real Estate Stock On CNBC’s ‘Final Trades’2/12 – BENZINGA
- Apple iPhone stands out: only smartphone to grow in China sales this January – Counterpoint 2/12 – MSN
$203.03 -1.05 (-0.51%) As of 2/12/2026 9:40 AM ET
- Amazon Stock Slump: Is This A Crash Or A Buying Opportunity? 2/12 – FORBES
- BETA Technologies: Amazon Surge Is A False Flag, But Vertical Integration Makes It A Buy 2/12 – SEEKINGALPHA
- ChatGPT picks 2 stocks to buy during February market crash 2/12 – FINBOLD
- Exclusive: Italian tax police search Amazon in new tax probe, sources say 2/12 – REUTERS
- Adastra Enters AWS Partner Greenfield Program to Accelerate Customers’ Migration to AWS and Realize AI Value2/12 – FINANCIALPOST
$310.87 -0.09 (-0.03%) As of 2/12/2026 9:40 AM ET
- My Top Quantum Pick: The Only Stock I’d Buy 2/12 – 247WALLST
- BlueBird 6 Unfolds: AST SpaceMobile Unlocks Commercial Growth (GOOGL)2/12 – MARKETBEAT
- TD Waterhouse Canada Inc. Grows Stake in Alphabet Inc. $GOOGL 2/12 – MARKETBEAT
- Why Alphabet’s 100-year sterling bond is raising new fears over debt-fuelled AI arms race 2/12 – CNBC
- Alphabet Stock: Is It Time to Buy the Dip?2/11 – FOOL
$667.59 -1.11 (-0.17%) As of 2/12/2026 9:40 AM ET
- COO Javier Olivan sold 517 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $663.19, for a total value of $342,869.23. Following the sale, the chief operating officer directly owned 9,098 shares in the company, valued at approximately $6,033,702.62. The trade was a 5.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
- Veltria Advisors Corp. Cuts Stock Position in Meta Platforms, Inc. $META2/12 – MARKETBEAT
- Unison Asset Management LLC Has $7.59 Million Stock Holdings in Meta Platforms, Inc. $META 2/12 – MARKETBEAT
- WhatsApp fully blocked in Russia as Moscow backs new platform and it is not Telegram. Check new alternative for Meta Platforms messenger 2/12 – MSN
- Meta attorneys fire back at claims made by state’s star witness in day three of trial2/12 – YAHOO
- Russia blocks WhatsApp as messaging app crackdown gathers pace 2/12 – CNBC
$403.63 -0.74 (-0.18%) As of 2/12/2026 9:40 AM ET
- Microsoft Deepens Sovereign Cloud And AI Push With Capgemini Alliance 2/12 – YAHOO
- Microsoft Corporation $MSFT Holdings Lifted by Verdence Capital Advisors LLC2/12 – MARKETBEAT
- Microsoft Corporation $MSFT is Violich Capital Management Inc.’s Largest Position2/12 – MARKETBEAT
- ESW Launches MissionReady365™ to Accelerate Microsoft 365 Staffing for Government Projects 2/12 – GLOBENEWSWIRE
- 3 Trillion-Dollar Stocks That Can Soar Up to 90% in 2026, According to Select Wall Street Analysts 2/12 – FOOL
Analysts’ Upgrades
Analog Devices (NASDAQ:ADI) was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $375.00 price target on the stock. This represents a 9.5% upside from the current price of $342.61.Huntington Ingalls Industries (NYSE:HII) was upgraded by analysts at Bank of America Corporation from an “underperform” rating to a “neutral” rating. They now have a $400.00 price target on the stock. This represents a 0.5% downside from the current price of $401.85.Hexcel (NYSE:HXL) was upgraded by analysts at Bank of America Corporation from an “underperform” rating to a “neutral” rating. They now have a $95.00 price target on the stock. This represents a 4.9% upside from the current price of $90.59.LuxExperience B.V. (NYSE:LUXE) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $14.00 price target on the stock, up previously from $9.00. This represents a 29.6% upside from the current price of $10.80.MercadoLibre (NASDAQ:MELI) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $2,800.00 price target on the stock, up previously from $2,650.00. This represents a 33.2% upside from the current price of $2,101.56.
VIEW MORE UPGRADES
Musk Warns. Trump Acts. Your Retirement May Depend on It (ad)With Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize.
That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works.
CLAIM YOUR FREE 2025 WEALTH PROTECTION GUIDE NOW
Analysts’ Downgrades
Arcellx (NASDAQ:ACLX) was downgraded by analysts at Rothschild & Co Redburn from a “buy” rating to a “neutral” rating. They now have a $82.00 price target on the stock. This represents a 18.6% upside from the current price of $69.13.Coinbase Global (NASDAQ:COIN) was downgraded by analysts at Monness Crespi & Hardt from a “buy” rating to a “neutral” rating. They now have a $120.00 price target on the stock. This represents a 20.4% downside from the current price of $150.70.Great Lakes Dredge & Dock(NASDAQ:GLDD) was downgraded by analysts at Noble Financial from an “outperform” rating to a “market perform” rating.The current price is $16.94.Kraft Heinz (NASDAQ:KHC) was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $22.00 price target on the stock. This represents a 9.5% downside from the current price of $24.32.Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at Rothschild & Co Redburn from a “buy” rating to a “neutral” rating. They now have a $24.00 price target on the stock. This represents a 30.3% upside from the current price of $18.42.Pfizer (NYSE:PFE) was downgraded by analysts at Daiwa Securities Group Inc. from an “outperform” rating to a “neutral” rating. They now have a $27.00 price target on the stock. This represents a 1.7% downside from the current price of $27.47.Sanofi (NASDAQ:SNY) was downgraded by analysts at Bank of America Corporation from a “buy” rating to a “neutral” rating.The current price is $46.80.Valvoline (NYSE:VVV) was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $35.00 price target on the stock, up previously from $30.00. This represents a 10.1% downside from the current price of $38.95.
VIEW MORE DOWNGRADES
Two AI Stocks Getting Quiet Attention (ad)Market volatility hasn’t disappeared — but investor behavior has changed.
Instead of chasing broad rallies, capital is increasingly flowing toward areas showing clear demand, real-world adoption, and long-term relevance. Artificial intelligence continues to stand out on all three fronts.
Across earnings calls and corporate spending plans, AI investment is no longer theoretical. It’s being deployed, measured, and expanded — even as other sectors lose momentum.
That shift is creating selective opportunities for investors paying attention.
2 AI STOCKS POSITIONED FOR THE NEXT PHASE OF GROWTH
Analysts’ New Coverage
Adherex Technologies (NASDAQ:FENC) is now covered by analysts at B. Riley Securities. They set a “buy” rating and a $16.00 price target on the stock. This represents a 97.2% upside from the current price of $8.11.Honda Motor (NYSE:HMC) is now covered by analysts at BNP Paribas Exane. They set an “underperform” rating and a $25.00 price target on the stock. This represents a 21.5% downside from the current price of $31.84.Sezzle (NASDAQ:SEZL) is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $85.00 price target on the stock. This represents a 36.1% upside from the current price of $62.46.USA Today (NYSE:TDAY) is now covered by analysts at Rosenblatt Securities. They set a “buy” rating and a $10.00 price target on the stock. This represents a 63.9% upside from the current price of $6.10.Toyota Motor (NYSE:TM) is now covered by analysts at BNP Paribas Exane. They set an “outperform” rating and a $290.00 price target on the stock. This represents a 19.5% upside from the current price of $242.67.Ermenegildo Zegna (NYSE:ZGN) is now covered by analysts at Morgan Stanley. They set an “equal weight” rating and a $11.00 price target on the stock. This represents a 0.9% upside from the current price of $10.90.
VIEW MORE NEW COVERAGE
Calendars from MarketBeat
U.S. Analyst RatingsCongressional BuyingCorporate BuybacksCryptocurrenciesDividend DeclarationsEarnings AnnouncementsEarnings Conference CallsFDA CalendarGap Up/Down StocksInsider TradesInitial Public Offerings (IPOs)Most Active StocksPercentage Gainers/DeclinersSector PerformanceShort InterestStock SplitsUnusual Options VolumeUnusual Trading VolumeGET 30 DAYS OF MARKETBEAT ALL ACCESS FREESign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
- Best-in-Class Portfolio MonitoringView the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
- Stock Ideas and RecommendationsGet daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
- Advanced Stock Screeners and Research ToolsIdentify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
Thank you for subscribing to MarketBeat!
MarketBeat empowers individual investors to make better investment decisions by providing up-to-the-minute financial information and independent market analysis.
If you have questions or concerns about your newsletter, please don’t hesitate to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.
If you wish to unsubscribe or change which emails you subscribe to, you may modify your subscription preferences or unsubscribe from this newsletter.
Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Sixth Floor, Sioux Falls, SD 57103. U.S.A..
Daily Bonus Content: Trump’s Final Shocking Act Begins February 24 (From Banyan Hill Publishing)
RJ Hamster
ISPC: A Small Cap with BIG Institutional Ambitions.
A message from our friends at Stocks.News
From Fragmented Supply Chains to Real-World Research Acceleration: How ISPC is Disrupting the Global Biospecimen Market
iSpecimen (NASDAQ: ISPC) is tackling one of the most persistent challenges in life sciences: sourcing human biospecimens efficiently and compliantly.
Its Amazon-like marketplace links thousands of researchers with hospitals, labs, and biobanks globally, enabling next-day quotes and rapid access to a wide range of specimens, from cerebrospinal fluid to fresh frozen tissue.
By streamlining the research supply chain, ISPC accelerates discovery timelines while delivering high-quality, documented samples that meet regulatory standards—a key differentiator in the $3–4 billion global biospecimen market.
The company continues to expand its network and partnerships, including collaborations with AI-powered pathology providers, enhancing both quality control and platform capabilities.
Backed by operational momentum and a flexible financial approach, ISPC is scaling a platform that addresses a massive industry inefficiency.
See how ISPC is quietly building the future of medical research infrastructure
Thank you for subscribing to The Early Bird, MarketBeat’s 7:00 AM newsletter that covers stories that will impact the stock market each day.
This message is a paid advertisement for Stocks.News, a third-party advertiser of The Early Bird and MarketBeat.
This message is a paid advertisement for iSpecimen Inc. (NASDAQ: ISPC) from Stocks.News and Organized Noise. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $50,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Stocks.News or Organized Noise. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding iSpecimen Inc. (NASDAQ: ISPC) on Organized Noise’ website for additional information about the relationship between Organized Noise and iSpecimen Inc. (NASDAQ: ISPC) .
If you have questions about your account, feel free to contact MarketBeat’s U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Sixth Floor, Sioux Falls, SD 57103. United States of America..
Featured Link: 7 High-Yield Dividend Stocks You Need to See (Click to Opt-In)
RJ Hamster
IPO Season Could Return in 2026
You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here.
Prefer to view this content on our website? Click here.
How to Trade SpaceX Without Trading SpaceX
IPOs are exciting for a reason: they create scarcity, headlines, and the promise of getting in early on “the next big thing.”
They’re also a coin flip.
Some IPOs roar out of the gate and never look back. Others open strong, fade fast, and punish late buyers who chased hype instead of fundamentals. Even well-known brands can disappoint once the roadshow excitement wears off and lockups, valuations, and reality set in.
That’s why one of the most effective ways to invest in an IPO—especially a high-profile one—is not to invest in the IPO directly.
The SpaceX buzz is building again
SpaceX has been one of the most anticipated IPO candidates in the world. And lately, that speculation has intensified.
A Reuters-sourced report published via Yahoo Finance said SpaceX has explored a blockbuster 2026 IPO that could raise more than $25 billion, potentially pushing valuation toward or above $1 trillion. That’s not a “routine” listing—if it happens, it could reshape the entire IPO calendar and spark a broader reopening of the new-issues market.
The potential appeal is obvious:
- SpaceX is the dominant U.S. private-space company by profile and launch cadence.
- Starlink continues to scale as a global satellite-internet business.
- Long-term ambitions (including Starship) keep the growth narrative alive.
The problem is that IPO timing and pricing are unknowable until they aren’t—by which point most of the “easy upside” is often already priced into the stock.
Sponsored by Decentralized Masters
The Fed is Trapped. Here’s Your Only Exit Strategy.
Every 8 hours, the U.S. adds $1B to the national debt. We’re at 120% debt-to-GDP. Greece collapsed at 130%. The Fed can’t win: cut rates, inflation spikes. Keep rates high, the debt spiral accelerates. Either way, your savings lose. A CFA Charterholder and ex-Wall Street banker built a 3-phase system that works regardless of which path the Fed chooses. Over 4,000 investors are using it now.
Watch the free training to see the ABN System that protects you from what’s coming →
Why IPO investing can be brutal
Even when the company is real, the “IPO trade” has structural risks:
- Valuation risk
Investment banks and selling shareholders generally want the highest possible price. That can mean IPO buyers pay full freight. - Volatility and liquidity traps
Early trading can be thin and emotional. Price swings can be violent, especially in a market that’s risk-sensitive. - Lockup dynamics
When lockups expire, early investors and insiders may sell. That supply can pressure shares regardless of business quality. - Hype cycles
Media attention often peaks at the IPO—not when fundamentals are best.
So instead of betting everything on one listing at one price on one day, it can make more sense to position for the broader IPO cycle—the environment that tends to benefit from a reopened new-issues market.
That’s where IPO-focused ETFs come in.
ETF: First Trust US Equity Opportunities ETF (SYM: FPX)
The diversified “U.S. IPO leaders” approach
FPX is built to provide exposure to U.S. companies relatively early in their public life, using a rules-based approach rather than single-stock guessing. First Trust describes FPX as an ETF designed around U.S. IPO exposure (and provides fund materials and index details through its official product page).
Why FPX can be useful in an IPO cycle
- Diversification: exposure to multiple newly public companies rather than a single IPO outcome.
- Rules-based construction: less reliance on narrative timing.
- Theme leverage: if the IPO market reopens, the “new listing ecosystem” often attracts incremental capital.
FPX last traded around $165.00.
Tradeoff to understand: FPX is not a direct SpaceX proxy. If SpaceX stays private—or if the listing comes with unexpected structure—FPX still functions as a broader IPO-cycle vehicle rather than a one-off bet.
Huge Alerts
BioStem Technologies (OTCQB: BSEM) is emerging as one of the most compelling small-cap MedTech companies as 2026 begins. The company just completed the acquisition of BioTissue Holdings’ surgical and wound care business, instantly expanding its footprint into hospital-based, acute, and surgical wound care.
With established product lines like Neox® and Clarix®, a nationwide sales force, and key GPO contracts, BioStem is now positioned to capture a $300–$350 million addressable market, spanning chronic and acute wound care, burns, and soft-tissue repair.
Zacks Small Cap Research has assigned BSEM a $25.50 price target, highlighting confidence in the company’s profitable growth, clinical validation, and expanding market presence.
Coupled with seven consecutive profitable quarters, strong gross margins of 88.5%, and $16 million in cash post-acquisition, BSEM is demonstrating operational excellence rarely seen in small-cap regenerative medicine.
Backed by clinically validated BioREtain® technology, FDA-level studies, and a potential Nasdaq uplisting in mid-2026, BSEM is gaining traction with both institutional investors and healthcare providers.
Discover why BSEM is setting the standard for profitable, clinically proven MedTech growth in 2026
ETF: Renaissance IPO ETF (SYM: IPO)
The “newly public basket” designed to reduce single-stock risk
For investors who want a clean, index-driven way to own newly public companies, Renaissance’s IPO ETF is one of the better-known options.
Renaissance explicitly states the fund “seeks to provide investors with the largest, most liquid US-listed newly public company stocks in one security,” aiming to reduce single-stock risk and avoid overlap with major core indices.
Additional index details commonly cited for IPO-focused funds: the ETF is based on the FTSE Renaissance IPO Indexand generally holds companies for a defined window after they go public (often up to three years), then rotates them out.
IPO last traded around $44.09.
Why IPO can work well for this theme
- Focuses on liquid newly public names (important—because many new listings trade poorly at first).
- Uses an index approach that can benefit from multiple winnersrather than needing one perfect call.
How this becomes a “SpaceX strategy” without SpaceX
If SpaceX truly moves toward a 2026 IPO with a $25B+ raise, that kind of deal can do more than create one tradable ticker—it can help reopen the IPO window for other high-profile private companies.
In that environment:
- investor appetite for new listings can improve,
- flows can rotate into “newly public” baskets, and
- IPO-themed ETFs can benefit from the broader cycle.
This is the central idea: instead of trying to win the IPO coin flip, it’s often more sensible to position for the second-order effect—the return of a more active IPO market.
TradeAlgo
Just Out: New AI Tool for Retail Traders
Peter Lynch generated 29.2% annual returns (1977-1990) with one philosophy: “The person who turns over the most rocks wins.” Hedge funds have analyst teams to uncover opportunities—retail traders typically don’t.
TradeAlgo changes that with AI-powered dark pool alerts. The system scans secret exchanges for unusual stock activity and texts you exact tickers, letting you spot volume surges and potential breakouts instantly.
Are there any other IPO rumors you’re keeping an eye on? What other sectors of the market are you focusing on in 2026? Hit “reply” to this email and let us know your thoughts!
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $6,500 and was received/will be received from Sideways Frequency.
This communication should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts.
We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.
This disclosure is made as of 02/12/2026.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You’re receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
RJ Hamster
RJ Hamster
A Scottish Voice for Scottish Wildlife – by Rob…
A significant step forward for Protect the Wild!
— Read on protectthewild.substack.com/p/a-scottish-voice-for-scottish-wildlife